JP6063380B2 - サンフィリポ症候群ｂ型の処置 - Google Patents
サンフィリポ症候群ｂ型の処置 Download PDFInfo
- Publication number
- JP6063380B2 JP6063380B2 JP2013516847A JP2013516847A JP6063380B2 JP 6063380 B2 JP6063380 B2 JP 6063380B2 JP 2013516847 A JP2013516847 A JP 2013516847A JP 2013516847 A JP2013516847 A JP 2013516847A JP 6063380 B2 JP6063380 B2 JP 6063380B2
- Authority
- JP
- Japan
- Prior art keywords
- naglu
- brain
- protein
- nmol
- lysosomal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000011580 syndromic disease Diseases 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title description 62
- 210000004556 brain Anatomy 0.000 claims description 231
- 102000004190 Enzymes Human genes 0.000 claims description 204
- 108090000790 Enzymes Proteins 0.000 claims description 204
- 238000007913 intrathecal administration Methods 0.000 claims description 187
- 108090000623 proteins and genes Proteins 0.000 claims description 175
- 102000004169 proteins and genes Human genes 0.000 claims description 167
- 210000001519 tissue Anatomy 0.000 claims description 160
- 230000002132 lysosomal effect Effects 0.000 claims description 124
- 239000000203 mixture Substances 0.000 claims description 124
- 210000004027 cell Anatomy 0.000 claims description 113
- 230000000694 effects Effects 0.000 claims description 79
- 102000037865 fusion proteins Human genes 0.000 claims description 79
- 108020001507 fusion proteins Proteins 0.000 claims description 79
- 238000012384 transportation and delivery Methods 0.000 claims description 59
- 210000000278 spinal cord Anatomy 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 230000007423 decrease Effects 0.000 claims description 56
- 230000008685 targeting Effects 0.000 claims description 54
- 238000010186 staining Methods 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 45
- 210000002569 neuron Anatomy 0.000 claims description 43
- 210000003712 lysosome Anatomy 0.000 claims description 41
- 230000001868 lysosomic effect Effects 0.000 claims description 41
- 210000004185 liver Anatomy 0.000 claims description 40
- 238000003860 storage Methods 0.000 claims description 40
- 230000002829 reductive effect Effects 0.000 claims description 32
- 208000024891 symptom Diseases 0.000 claims description 31
- 210000004885 white matter Anatomy 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 238000001990 intravenous administration Methods 0.000 claims description 27
- 230000002093 peripheral effect Effects 0.000 claims description 26
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 25
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 25
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 24
- 210000001638 cerebellum Anatomy 0.000 claims description 24
- 102000057877 human IGF2 Human genes 0.000 claims description 24
- 210000003710 cerebral cortex Anatomy 0.000 claims description 21
- 210000005013 brain tissue Anatomy 0.000 claims description 20
- 210000004705 lumbosacral region Anatomy 0.000 claims description 20
- 210000001159 caudate nucleus Anatomy 0.000 claims description 19
- 210000002418 meninge Anatomy 0.000 claims description 19
- 230000002477 vacuolizing effect Effects 0.000 claims description 16
- 210000004498 neuroglial cell Anatomy 0.000 claims description 15
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 claims description 11
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 10
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 9
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims description 9
- 210000004379 membrane Anatomy 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 210000001259 mesencephalon Anatomy 0.000 claims description 9
- 210000000449 purkinje cell Anatomy 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 210000004884 grey matter Anatomy 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 210000002637 putamen Anatomy 0.000 claims description 7
- 210000005250 spinal neuron Anatomy 0.000 claims description 7
- 239000002052 molecular layer Substances 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 5
- 206010011878 Deafness Diseases 0.000 claims description 4
- 210000000576 arachnoid Anatomy 0.000 claims description 4
- 230000010370 hearing loss Effects 0.000 claims description 4
- 231100000888 hearing loss Toxicity 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 210000000478 neocortex Anatomy 0.000 claims description 4
- 210000004786 perivascular cell Anatomy 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 238000012385 systemic delivery Methods 0.000 claims description 3
- 208000030979 Language Development disease Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 156
- 238000002347 injection Methods 0.000 description 122
- 239000007924 injection Substances 0.000 description 122
- 238000000034 method Methods 0.000 description 99
- 230000001225 therapeutic effect Effects 0.000 description 84
- 241000699670 Mus sp. Species 0.000 description 80
- 238000009472 formulation Methods 0.000 description 66
- 239000003814 drug Substances 0.000 description 61
- 210000003169 central nervous system Anatomy 0.000 description 52
- 229940124597 therapeutic agent Drugs 0.000 description 52
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 41
- 238000012744 immunostaining Methods 0.000 description 40
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 36
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 36
- 239000002904 solvent Substances 0.000 description 35
- 230000000153 supplemental effect Effects 0.000 description 32
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 29
- 230000002950 deficient Effects 0.000 description 28
- 229920002683 Glycosaminoglycan Polymers 0.000 description 27
- 238000009825 accumulation Methods 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 210000001103 thalamus Anatomy 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000003364 immunohistochemistry Methods 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 20
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 20
- 208000015439 Lysosomal storage disease Diseases 0.000 description 20
- 241000700159 Rattus Species 0.000 description 20
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000009467 reduction Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 210000000133 brain stem Anatomy 0.000 description 15
- 238000009826 distribution Methods 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 108700012441 IGF2 Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 210000004720 cerebrum Anatomy 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000001130 astrocyte Anatomy 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 239000003018 immunosuppressive agent Substances 0.000 description 11
- 238000007917 intracranial administration Methods 0.000 description 11
- 230000002025 microglial effect Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 10
- 210000001218 blood-brain barrier Anatomy 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 230000004700 cellular uptake Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- -1 mannose-6-phosphate diester Chemical class 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000002739 subcortical effect Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 231100000041 toxicology testing Toxicity 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 238000002641 enzyme replacement therapy Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000002861 ventricular Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 238000012742 biochemical analysis Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 5
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 5
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 5
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 159000000007 calcium salts Chemical class 0.000 description 5
- 210000003198 cerebellar cortex Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102100021869 Tyrosine aminotransferase Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000008228 bacteriostatic water for injection Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007914 intraventricular administration Methods 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000004952 protein activity Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 101150048357 Lamp1 gene Proteins 0.000 description 3
- 108010031099 Mannose Receptor Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 210000004565 granule cell Anatomy 0.000 description 3
- 238000007489 histopathology method Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 229940124589 immunosuppressive drug Drugs 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000569 multi-angle light scattering Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000037340 Rare genetic disease Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 description 2
- 239000001852 Succistearin Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 231100000269 corneal opacity Toxicity 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000000819 hypertonic solution Substances 0.000 description 2
- 229940021223 hypertonic solution Drugs 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010045758 lysosomal proteins Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000004320 sodium erythorbate Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KKMIHKCGXQMFEU-UHFFFAOYSA-N 2-[dimethyl(tetradecyl)azaniumyl]acetate Chemical group CCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O KKMIHKCGXQMFEU-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
- FZLJPEPAYPUMMR-RTRLPJTCSA-N 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(O)=O FZLJPEPAYPUMMR-RTRLPJTCSA-N 0.000 description 1
- DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102100037364 Craniofacial development protein 1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 101150110503 END3 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101001018296 Protopolybia exigua Mastoparan-3 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010041467 Speech disorder developmental Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000802478 Sylvirana guentheri Brevinin-2GHa Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical group [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000219 ependymocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000005112 optic tract Anatomy 0.000 description 1
- 230000004421 optic tracts Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 210000000463 red nucleus Anatomy 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000003863 superior colliculi Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US61/358,857 | 2010-06-25 | ||
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US61/360,786 | 2010-07-01 | ||
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US61/387,862 | 2010-09-29 | ||
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US61/435,710 | 2011-01-24 | ||
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US61/442,115 | 2011-02-11 | ||
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US61/476,210 | 2011-04-15 | ||
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| US61/495,268 | 2011-06-09 | ||
| PCT/US2011/041928 WO2011163652A2 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015246589A Division JP2016094451A (ja) | 2010-06-25 | 2015-12-17 | サンフィリポ症候群ｂ型の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542913A JP2013542913A (ja) | 2013-11-28 |
| JP2013542913A5 JP2013542913A5 (OSRAM) | 2014-08-14 |
| JP6063380B2 true JP6063380B2 (ja) | 2017-01-18 |
Family
ID=46888842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516847A Expired - Fee Related JP6063380B2 (ja) | 2010-06-25 | 2011-06-25 | サンフィリポ症候群ｂ型の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110318327A1 (OSRAM) |
| EP (1) | EP2585105B1 (OSRAM) |
| JP (1) | JP6063380B2 (OSRAM) |
| KR (1) | KR20130043166A (OSRAM) |
| CN (1) | CN103269709A (OSRAM) |
| AU (2) | AU2011270672B2 (OSRAM) |
| CA (1) | CA2805449A1 (OSRAM) |
| ES (1) | ES2643015T3 (OSRAM) |
| MX (1) | MX2013000324A (OSRAM) |
| NZ (2) | NZ702801A (OSRAM) |
| WO (1) | WO2011163652A2 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| HRP20170698T1 (hr) * | 2008-05-07 | 2017-09-22 | Biomarin Pharmaceutical Inc. | Lizosomski usmjereni peptidi i njihove uporabe |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| BR112012033197A2 (pt) | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | métodos e composições para liberação de cns de n-sulfatase de heparano. |
| PT2588130T (pt) | 2010-06-25 | 2016-11-25 | Shire Human Genetic Therapies | Entrega de agentes terapêuticos no cns |
| KR102720061B1 (ko) | 2010-06-25 | 2024-10-22 | 다케다 파머수티컬 컴패니 리미티드 | 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들 |
| WO2012012742A2 (en) | 2010-07-22 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| JP6175372B2 (ja) * | 2011-03-04 | 2017-08-02 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ポリペプチド組成物用ペプチドリンカーおよびその使用方法 |
| RU2014117291A (ru) | 2011-10-12 | 2015-11-20 | Синаджева Биофарма Корп. | Рекомбинантный человеческий белок naglu и его применение |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| HUE039334T2 (hu) | 2012-11-27 | 2018-12-28 | Biomarin Pharm Inc | Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai |
| FR3011468B1 (fr) * | 2013-10-04 | 2015-12-04 | Inventiva | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
| WO2015200675A1 (en) * | 2014-06-25 | 2015-12-30 | Shire Human Genetic Therapies, Inc. | Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase |
| JP6623213B2 (ja) | 2014-08-11 | 2019-12-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | リソソーム酵素に融合したマンノース−６−リン酸含有ペプチド |
| US10603364B2 (en) * | 2014-08-11 | 2020-03-31 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| AU2015323966A1 (en) | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| US10556015B2 (en) * | 2014-10-24 | 2020-02-11 | Criteo S.A. | Lysosomal targeting of enzymes, and uses thereof |
| MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| RU2751235C2 (ru) * | 2016-02-24 | 2021-07-12 | Байомарин Фармасьютикал Инк. | Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения |
| JP2020002130A (ja) | 2018-06-25 | 2020-01-09 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| US20230323326A1 (en) * | 2020-08-28 | 2023-10-12 | Jcr Pharmaceuticals Co., Ltd. | Mutant of alpha-N-Acetylglucosaminidase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| AU3113700A (en) | 1998-12-07 | 2000-06-26 | Genzyme Corporation | Treatment of pompe's disease |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| CA2463473A1 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| EP1514106A4 (en) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| WO2004064750A2 (en) | 2003-01-22 | 2004-08-05 | Duke University | Improved constructs for expressing lysosomal polypeptides |
| EP1638605B1 (en) * | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| CN1922313B (zh) | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
| GB0611463D0 (en) * | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| US20090041741A1 (en) | 2007-03-06 | 2009-02-12 | Saint Louis University | Modified enzyme and treatment method |
| HRP20170698T1 (hr) * | 2008-05-07 | 2017-09-22 | Biomarin Pharmaceutical Inc. | Lizosomski usmjereni peptidi i njihove uporabe |
| BR112012033197A2 (pt) * | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | métodos e composições para liberação de cns de n-sulfatase de heparano. |
-
2011
- 2011-06-25 MX MX2013000324A patent/MX2013000324A/es unknown
- 2011-06-25 JP JP2013516847A patent/JP6063380B2/ja not_active Expired - Fee Related
- 2011-06-25 AU AU2011270672A patent/AU2011270672B2/en not_active Ceased
- 2011-06-25 WO PCT/US2011/041928 patent/WO2011163652A2/en not_active Ceased
- 2011-06-25 KR KR1020137001751A patent/KR20130043166A/ko not_active Ceased
- 2011-06-25 CN CN2011800407953A patent/CN103269709A/zh active Pending
- 2011-06-25 US US13/168,969 patent/US20110318327A1/en not_active Abandoned
- 2011-06-25 NZ NZ702801A patent/NZ702801A/en not_active IP Right Cessation
- 2011-06-25 ES ES11799039.0T patent/ES2643015T3/es active Active
- 2011-06-25 CA CA2805449A patent/CA2805449A1/en not_active Abandoned
- 2011-06-25 NZ NZ605871A patent/NZ605871A/en not_active IP Right Cessation
- 2011-06-25 EP EP11799039.0A patent/EP2585105B1/en active Active
-
2017
- 2017-04-10 AU AU2017202344A patent/AU2017202344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2585105A2 (en) | 2013-05-01 |
| EP2585105B1 (en) | 2017-08-09 |
| WO2011163652A2 (en) | 2011-12-29 |
| MX2013000324A (es) | 2013-02-01 |
| WO2011163652A3 (en) | 2013-07-11 |
| CA2805449A1 (en) | 2011-12-29 |
| AU2017202344A1 (en) | 2017-04-27 |
| AU2011270672A1 (en) | 2013-02-14 |
| US20110318327A1 (en) | 2011-12-29 |
| NZ605871A (en) | 2015-02-27 |
| JP2013542913A (ja) | 2013-11-28 |
| NZ702801A (en) | 2016-08-26 |
| ES2643015T3 (es) | 2017-11-21 |
| KR20130043166A (ko) | 2013-04-29 |
| EP2585105A4 (en) | 2014-07-09 |
| CN103269709A (zh) | 2013-08-28 |
| AU2011270672B2 (en) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6063380B2 (ja) | サンフィリポ症候群ｂ型の処置 | |
| US11065307B2 (en) | Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moiety | |
| JP6045492B2 (ja) | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 | |
| CN103282046B (zh) | 芳基硫酸酯酶 a cns 递送的方法和组合物 | |
| US20220133863A1 (en) | Treatment of sanfilippo syndrome type b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150618 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150909 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151217 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160914 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6063380 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |